Human EGFR Knockout Cell Line-T47D
Cat.No. : CSC-RT2795
Host Cell: T47D Target Gene: EGFR
Size: 1x10^6 cells/vial, 1mL Validation: Sequencing
Inquire for Price
Cell Line Information
Cell Culture Information
Safety and Packaging
| Cat. No. | CSC-RT2795 |
| Cell Line Information | This cell is a stable cell line with a homozygous knockout of human EGFR using CRISPR/Cas9. |
| Target Gene | EGFR |
| Host Cell | T47D |
| Size Form | 1 vial (>10^6 cell/vial) |
| Shipping | Dry ice package |
| Storage | Liquid Nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Inquiry
Background
Applications
The epidermal growth factor receptor (EGFR) gene is a key component in a complex network of cellular processes, particularly those related to cell growth, proliferation, and differentiation. EGFR is a transmembrane protein that, when bound to its specific ligand, undergoes dimerization and autophosphorylation, initiating a cascade of downstream signaling pathways. These pathways include the Ras-Raf-MEK-ERK pathway, the PI3K-AKT pathway, and the JAK-STAT pathway, which together promote a variety of cellular responses.
EGFR gene mutations are strongly associated with several types of cancer, most notably non-small cell lung cancer (NSCLC). These mutations can lead to aberrant activation of the EGFR signaling pathway, resulting in uncontrolled cell division and tumor growth. In NSCLC, two major types of EGFR mutations are commonly observed: deletions in exon 19 and L858R point mutations in exon 21. In addition to lung cancer, EGFR variants have been associated with other malignancies such as glioblastoma, colorectal cancer, and head and neck cancer. In glioblastoma, EGFR amplification and the presence of the EGFRvIII variant promote aggressive tumor behavior and resistance to conventional therapies. Similarly, in colorectal cancer, EGFR overexpression is associated with a poor prognosis and has led to the development of monoclonal antibodies such as cetuximab and panitumumab, which target the extracellular domain of the receptor.
The Human EGFR Knockout Cell Line - T47D is derived from human breast cancer cells and is a key tool in a variety of research areas. Here are the main applications of this cell line:
Cancer Research: By knocking out the EGFR gene in T47D cells, researchers can study the role of this gene in cancer pathogenesis and identify potential therapeutic targets.
Signal Transduction Research: EGFR is a key receptor in the signaling cascade that regulates cell proliferation, differentiation, and survival. Using the EGFR knockout cell line, scientists can unravel complex signaling networks and understand the downstream effects when EGFR signaling is absent, providing a deeper understanding of cellular communication.
Functional Genomics: This cell line can be used to study the functional genomics of EGFR and its interactions with other genetic elements.
Drug Screening: Researchers use these cell lines to screen for drugs that can effectively target pathways activated by EGFR. This model helps to evaluate the efficacy, potential toxicity, and mechanism of action of new compounds, thereby accelerating the drug discovery process.
Biomarker Identification: Researchers use this cell line to identify biomarkers associated with the presence or absence of EGFR. These biomarkers can be used for diagnostic purposes or to predict patient response to therapies targeting the EGFR pathway, thereby providing personalized treatment strategies.
For research use only. Not intended for any clinical use.
